Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Schattenberg
L Stump

Showing results (331-340 of 392) with videos related to

Pageof 40
Sort By:
Journal of Medicinal Chemistry|April 2, 2004
NR2B-selective N-methyl-D-aspartate antagonists: synthesis and evaluation of 5-substituted benzimidazolesJohn A McCauley, Cory R Theberge, Joseph J Romano, et al.
JAMA Network Open|November 6, 2025
Cost-Effectiveness of MASH Diagnosis and Management Approaches Among Those With Type 2 DiabetesJeffrey V Lazarus, Leire Agirre-Garrido, Luis Antonio Díaz, et al.
Bioorganic & Medicinal Chemistry Letters|December 12, 2001
Non-peptide alpha(v)beta(3) antagonists. Part 3: identification of potent RGD mimetics incorporating novel beta-amino acids as aspartic acid replacementsPaul J Coleman, Karen M Brashear, Cecilia A Hunt, et al.
Bioorganic & Medicinal Chemistry Letters|January 30, 2017
Discovery of MK-1832, a Kv1.5 inhibitor with improved selectivity and pharmacokineticsScott E Wolkenberg, M Brad Nolt, Mark T Bilodeau, et al.
Bioorganic & Medicinal Chemistry Letters|March 18, 2003
Orally efficacious NR2B-selective NMDA receptor antagonistsChristopher F Claiborne, John A McCauley, Brian E Libby, et al.
Hepatology (Baltimore, Md.)|January 24, 2021
Administrative Coding in Electronic Health Care Record-Based Research of NAFLD: An Expert Panel Consensus StatementHannes Hagström, Leon A Adams, Alina M Allen, et al.
BMJ Open|May 30, 2025
Global research initiative for patient screening on MASH (GRIPonMASH) protocol: rationale and design of a prospective multicentre studyVivian D de Jong, Marco Alings, Radan Bruha, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|February 16, 2021
Disease burden and economic impact of diagnosed non-alcoholic steatohepatitis in five European countries in 2018: A cost-of-illness analysisJörn M Schattenberg, Jeffrey V Lazarus, Philip N Newsome, et al.
Science Translational Medicine|December 3, 2020
Transcriptomic profiling across the nonalcoholic fatty liver disease spectrum reveals gene signatures for steatohepatitis and fibrosisOlivier Govaere, Simon Cockell, Dina Tiniakos, et al.
The Lancet Regional Health. Europe|June 10, 2026
Diagnostic innovation and models of care to improve fibrosis detection and risk stratification in steatotic liver diseaseNicola Pugliese, Trenton M White, Paul N Brennan, et al.
Pageof 40

Showing results (331-340 of 392) with videos related to

Sort By:
Pageof 40
Journal of Medicinal Chemistry|April 2, 2004
NR2B-selective N-methyl-D-aspartate antagonists: synthesis and evaluation of 5-substituted benzimidazolesJohn A McCauley, Cory R Theberge, Joseph J Romano, et al.
JAMA Network Open|November 6, 2025
Cost-Effectiveness of MASH Diagnosis and Management Approaches Among Those With Type 2 DiabetesJeffrey V Lazarus, Leire Agirre-Garrido, Luis Antonio Díaz, et al.
Bioorganic & Medicinal Chemistry Letters|December 12, 2001
Non-peptide alpha(v)beta(3) antagonists. Part 3: identification of potent RGD mimetics incorporating novel beta-amino acids as aspartic acid replacementsPaul J Coleman, Karen M Brashear, Cecilia A Hunt, et al.
Bioorganic & Medicinal Chemistry Letters|January 30, 2017
Discovery of MK-1832, a Kv1.5 inhibitor with improved selectivity and pharmacokineticsScott E Wolkenberg, M Brad Nolt, Mark T Bilodeau, et al.
Bioorganic & Medicinal Chemistry Letters|March 18, 2003
Orally efficacious NR2B-selective NMDA receptor antagonistsChristopher F Claiborne, John A McCauley, Brian E Libby, et al.
Hepatology (Baltimore, Md.)|January 24, 2021
Administrative Coding in Electronic Health Care Record-Based Research of NAFLD: An Expert Panel Consensus StatementHannes Hagström, Leon A Adams, Alina M Allen, et al.
BMJ Open|May 30, 2025
Global research initiative for patient screening on MASH (GRIPonMASH) protocol: rationale and design of a prospective multicentre studyVivian D de Jong, Marco Alings, Radan Bruha, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|February 16, 2021
Disease burden and economic impact of diagnosed non-alcoholic steatohepatitis in five European countries in 2018: A cost-of-illness analysisJörn M Schattenberg, Jeffrey V Lazarus, Philip N Newsome, et al.
Science Translational Medicine|December 3, 2020
Transcriptomic profiling across the nonalcoholic fatty liver disease spectrum reveals gene signatures for steatohepatitis and fibrosisOlivier Govaere, Simon Cockell, Dina Tiniakos, et al.
The Lancet Regional Health. Europe|June 10, 2026
Diagnostic innovation and models of care to improve fibrosis detection and risk stratification in steatotic liver diseaseNicola Pugliese, Trenton M White, Paul N Brennan, et al.
Pageof 40